CLEARWATER, Fla., April 1, 2026 /CNW/ - On March 31, 2026 following completion of the Transaction (as defined below), Jordan Atkins (the "Acquiror") acquired control and direction of a total of 2,084,367 subordinate voting shares ("SVS") and 41,050 proportionate voting shares ("PVS") in the capital of TelyRx Holdings Inc., formerly known as Apolo V Acquisition Corp. ("TelyRx" or the "Company").
On March 31, 2026, the Company completed the proposed transaction contemplated by the business combination agreement dated January 19, 2026, as amended (the "Business Combination Agreement") involving TelyRx, Inc., TelyRx Finco Inc., 1001474388 Ontario Inc. and Apolo V MergerCo Inc to complete a go-public transaction for TelyRx, Inc. (the "Transaction"). The Transaction constitutes Apolo V Acquisition Corp.'s "Qualifying Transaction" under Policy 2.4 – Capital Pool Companies of TSX Venture Exchange (the "TSXV").
In connection with the Transaction, as more fully described in Apolo V Acquisition Corp.'s filing statement (the "Filing Statement") dated March 24, 2026, the parties completed a series of steps (as defined in the Filing Statement) including the following: TelyRx Private Placement; Consolidation; Share Capital Reorganization; conversion of Subscription Receipts; Amalgamation and Merger.
Prior to the closing of the transactions contemplated by the Business Combination Agreement and Filing Statement, the Acquiror did not hold any securities of TelyRx.
Following closing of the transactions contemplated by the Business Combination Agreement and Filing Statement (including a purchase by the Acquiror of 716,026 subscription receipts at a price of C$4.50 in connection with the TelyRx Private Placement, for a total purchase price of C$3,222,117.00), the Acquiror acquired control and direction of a total of 2,084,367 SVS and 41,050 PVS. On the basis of 26,353,729 SVS and 224,967 PVS issued and outstanding at closing of the Transaction, the Acquiror holds 7.91% SVS and 18.25% PVS on a non-diluted basis, and a combined total of 20.32% (6,186,367 SVS) on a partially diluted basis, assuming exercise of the PVS.
TelyRx's head office is located at 24761 US Highway 19 North, Clearwater, Florida, USA, 33763.
The Acquiror will file an early warning report with the applicable securities regulators in Canada with respect to the foregoing matters pursuant to NI 62-103, a copy of which will be available under the Issuer's profile on SEDAR+ at www.sedarplus.ca. The address for the acquiror is 24641 US HWY 19 N Clearwater, Florida, 33763.
SOURCE Jordan Atkins
A copy of the early warning report can be obtained by contacting the Acquiror by phone at 727-482-0998.
Share this article